ÁRÁngel Romo-Navarro

Ángel Romo-Navarro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ángel Romo-Navarro has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unexpected yellow nodules in the esophagus: When common histology becomes uncommon

    by María Dolores Baños Salmerón, Ana Rosa Parra Tercero, Ángel Romo-Navarro, Carlos Vicente Hernández

  • Open Access

    Prognostic value of Ki-67 in non-metastatic colorectal adenocarcinoma: a retrospective study

    by Ángel Romo-Navarro, Irene García-Camacha Gutiérrez, Mariano Amo-Salas, Ana Rosa Parra-Tercero, María Recuero-Pradillo, César Sánchez-Muñoz, Cristina María Murillo Lázaro, Esperanza Carabias López, Raquel Sánchez Simón, Carlos Quimbayo-Arcila, et al.

    Background: Ki-67 is a cellular proliferation marker with an established prognostic role in several types of human tumors, whereas its prognostic significance in colorectal cancer remains uncertain. We assessed its prognostic value in an independent retrospective cohort of patients with non-metastatic colorectal adenocarcinoma. Methods: Overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan–Meier survival analysis and Cox proportional hazards regression, both in the overall cohort and stratified according to adjuvant therapy. Results: Among 207 cases, 132 (63.8%) and 75 (36.2%) showed high (≥ 50%) and low (< 50%) Ki-67, respectively. Kaplan–Meier analysis showed no significant differences in OS according to Ki-67 status ( p = 0.158), whereas DFS differed significantly ( p = 0.032). Fifteen-year DFS was 59% in the high Ki-67 group compared with 46% in the low Ki-67 group. In stratified multivariable Cox regression analysis, higher Ki-67 was significantly associated with a lower hazard of a DFS event among patients receiving adjuvant therapy (hazard ratio per 1-percentage-point increase = 0.954, 95% confidence interval: 0.925–0.984; p = 0.003). Conclusions: In patients with non-metastatic colorectal adenocarcinoma receiving conventional adjuvant therapy, low Ki-67 (< 50%) may identify a subgroup with significantly shorter DFS.

  • Primary vulvar extramammary Paget disease associated with herpes simplex virus infection: A rare case report

    by Pablo Recalde Puig, Jorge Martínez Boix, Ángel Romo-Navarro, Sara Arnedo Villarreal, Lidia Carbonero Jiménez, Esperanza Carabias López

  • Open Access

    Disease-Free Survival of Patients with Stage II Stroma-Rich Colorectal Adenocarcinomas with Microsatellite Stability

    by Ángel Romo-Navarro, Juan Ruiz Martín, Irene García-Camacha Gutiérrez, Mariano Amo-Salas, María Recuero Pradillo, César Sánchez-Muñoz, Cristina María Murillo Lázaro, Esperanza Carabias López, Raquel Sánchez Simón, Carlos Quimbayo-Arcila, et al.

    Up to 25% of stage II colorectal adenocarcinomas recur within the first five years after diagnosis. The assessment of the stromal percentage, recently incorporated into the TNM classification system, may represent a particularly relevant predictive factor for recurrence in cases with microsatellite stability. We evaluated disease-free survival (DFS) in an independent retrospective cohort, measured the stromal percentage across the entire invasive front of the tumor, and assessed the interobserver agreement of this measurement method. Among 131 cases, 16 (12.2%) showed a high stromal percentage and 115 (87.8%) a low one. A high stromal percentage was associated with high-grade budding (p = 0.006). The 5-year DFS was 57% for high-stroma cases versus 76% for low-stroma cases (p < 0.001). Lymphatic invasion (HR: 16.513; p < 0.001) and a high stromal percentage (HR: 4.366; p = 0.006) had a statistically significant correlation with DFS. Interobserver agreement for global stromal assessment was very good (kappa index = 0.870; p < 0.001). In conclusion, the stromal percentage may be a predictive factor for recurrence, particularly relevant in stage II microsatellite-stable colorectal adenocarcinomas. Global stromal assessment appears to be a simple and easily reproducible method.


  • Open Access

    Performance and Prognostic Relevance of Lymph Node Assessment by One-Step Nucleic Acid Amplification Assay in Rectal Cancer: A Multicenter Study

    by Qing Liu, Sandra Lopez-Prades, Karmele Saez de Gordoa, Maite Rodrigo-Calvo, Mireia Garcia, Juan Ruiz Martin, Angel Romo, Ignacio Pinilla, Jordi Tarragona, Begoña Otero Alen, et al.

    Background/Objectives: Lymph node metastases (LNM) undetected by standard hematoxylin and eosin (H&E) have been associated with unfavorable prognosis in colorectal cancer. The One-Step Nucleic Acid Amplification (OSNA) assay has demonstrated superior sensitivity in detecting LNM compared to H&E. We aimed to assess the performance of OSNA in detecting LNM, as well as its prognostic value in rectal cancer (RC) patients. Methods: Lymph nodes (LNs) of patients from 15 centers were analyzed by both H&E and OSNA. The total tumor load (TTL) was defined as the sum of cytokeratin 19 mRNA copies/µL in all LNs from a surgical specimen, using a threshold of 250 copies/μL for OSNA positivity. Cox proportional hazard regression was used to assess the effect of TTL ≥ 250 or 6000 copies/μL on cancer-specific survival (CSS) and recurrence-free survival (RFS), with Firth’s method applied to account for low event rate. Results: A total of 97 RC patients were included. Of these, 84 patients were eligible for survival analysis. The sensitivity and specificity of OSNA, compared to H&E, were 91.7% and 84.7%, respectively. TTL ≥ 6000 versus 6000 copies/μL, only TTL ≥ 6000 copies/μL was significantly associated with worse CSS and RFS. Conclusions: The OSNA assay is highly sensitive for detecting LNM in RC patients. A TTL of ≥6000 copies/μL could identify a subset of RC patients with worse CSS and RFS who might benefit from adjuvant treatment or intensive surveillance.